In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agon...
As oncology care becomes increasingly complex, traditional attribution models used in value-based care programs may no longer fully reflect how patients ar...
SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired CMIC, INC., a specialized provider of...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, introd...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an ex...
First Foundation Labs (1FL), a life sciences AI company pioneering clinical and translational reasoning spun out of Luma Group, announced a collaboration...
Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ch...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
UCB and Biogen Inc.announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS G...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
© 2026 Biopharma Boardroom. All Rights Reserved.
